Signal2026-06-25
ClinicalTrials.gov

[PHASE3] Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas

Part of

Emerging Cancer Biomarker Techniques

Open primary sourceRead on Substack